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Slow-Release Formulation of Cowpea Mosaic Virus for 
In Situ Vaccine Delivery to Treat Ovarian Cancer
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and Nicole F. Steinmetz*
DOI: 10.1002/advs.201700991
chemotherapies are usually initially effec-
tive in treating ovarian cancer, the devel-
opment of platinum resistance often 
leads to disease recurrence, making clear 
that novel and more effective treatment 
strategies are needed.[1] Immunothera-
pies hold great promise and a variety are 
currently under investigation for treat-
ment of ovarian cancer and other malig-
nancies.[2–5] We recently demonstrated 
the efficacy of an in situ vaccination 
strategy using the nanoparticles formed 
by the plant virus cowpea mosaic virus 
(CPMV); efficacy was demonstrated in 
several tumor types, including ovarian 
cancer.[6] An in situ vaccine works 
through direct administration of an 
immune-stimulatory agent, here CPMV, 
into the local tumor environment to 
reverse tumor-mediated immunosuppres-
sion and resensitize the immune system 
to tumor specific antigens. A particular 
advantage of this approach is that in 
situ vaccines are not limited by the pres-
ence of known antigens in tumor tissue.[7] The in situ vaccine 
triggers innate and adaptive antitumor responses, where the 
tumor itself serves as the antigen source eliminating the need 
to determine specific antigens for a given malignancy.[7,8]
The plant viral nanoparticle cowpea mosaic virus (CPMV) is shown to be an 
effective immunotherapy for ovarian cancer when administered as in situ vaccine 
weekly, directly into the intraperitoneal (IP) space in mice with disseminated 
tumors. While the antitumor efficacy is promising, the required frequency of 
administration may pose challenges for clinical implementation. To overcome 
this, a slow release formulation is developed. CPMV and polyamidoamine 
generation 4 dendrimer form aggregates (CPMV-G4) based on electrostatic 
interactions and as a function of salt concentration, allowing for tailoring 
of aggregate size and release of CPMV. The antitumor efficacy of a single 
administration of CPMV-G4 is compared to weekly administration of soluble 
CPMV in a mouse model of peritoneal ovarian cancer and found to be as 
effective at reducing disease burden as more frequent administrations of soluble 
CPMV; a single injection of soluble CPMV, does not significantly slow cancer 
development. The ability of CPMV-G4 to control tumor growth following a single 
injection is likely due to the continued presence of CPMV in the IP space leading 
to prolonged immune stimulation. This enhanced retention of CPMV and its 
antitumor efficacy demonstrates the potential for viral–dendrimer hybrids to be 
used for delayed release applications.
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1. Introduction
Ovarian cancer is the leading cause of death among gyneco-
logic malignancies in the United States. While platinum 
[+]Present address: Department of Bioengineering, University of Califor-
nia, Berkeley, California, USA 94720.
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In our previous study we demonstrated that in a synge-
neic, orthotopic mouse model of ovarian cancer, weekly 
intraperitoneal (IP) treatment using the CPMV in situ vac-
cine significantly delayed tumor growth and improved sur-
vival.[6] Injection of CPMV into cancer tissue induced a 
potent immune response that is thought to be related, in 
part, by conversion of the resident immune suppressive 
neutrophils present in tumors to pro-inflammatory type 
neutrophils. These activated neutrophils are capable of both 
directly killing tumor cells and priming T cells and NK cells 
toward antitumor activity.[6] While IP infusions of chemo-
therapies are currently approved for use clinically, and have 
been shown to provide a survival advantage in the treatment 
of ovarian cancer, this method of administration is underu-
tilized. In contrast to intravenous (IV) administration that 
can be done in the out-patient setting, IP administration 
often requires a hospital admission leading to increased cost 
and decreased quality of life.[9,10] Therefore, to alleviate the 
need for repeat administration, we set out to develop a slow-
release formulation of the CPMV in situ vaccine that would 
maintain sustained immune stimulation without the need 
for repeat IP injections. Maintaining an immunostimulatory 
effect through depot formation could reduce the number 
of IP administrations, making this treatment strategy more 
attainable for clinical implementation.
A number of slow-release formulations of cancer drugs 
and immunotherapies are currently under investigation;[11,12] 
these include hydrogels for delayed release of tumor associ-
ated antigens,[13] chemotherapeutics,[14] and a variety of other 
cargo including nucleic acids,[15] as well as microparticle[11] 
and microneedle[16] administration of antibodies for immuno-
therapy. These diverse approaches all seek to improve cancer 
treatment efficacy by maintaining a constant therapeutic 
concentration and improve cancer patient quality of life by 
reducing the number of administrations.
In this work, we aimed to develop slow-release assem-
blies of CPMV making use of charged dendrimers and 
electrostatic self-assembly protocols. While zwitterionic in 
nature, CPMV carries an overall negative surface charge, 
therefore we chose to program coassembly with positively-
charged polyamidoamine (PAMAM) dendrimers. A variety 
of different dendrimer formulations are under investigation 
for use in drug delivery and nanomedicines; they have the 
advantage of being highly tunable, multivalent, and pos-
sessing a low polydispersity.[17] In addition to their use in 
drug delivery, dendrimers have been used in combination 
with oncolytic adenovirus in order to improve intratumoral 
accumulation[18] and in virus–dendrimer assemblies as a 
method to create well-controlled higher order structure on 
a nanoscale-to-mesoscale level.[15] PAMAM dendrimers in 
particular are well-understood, uniform, and commercially 
available; our lab has successively used them in the past to 
create virus–dendrimer hybrid materials for photon capture 
applications.[19] The potential for in situ vaccination applica-
tions using virus–dendrimer hybrids however, has not yet 
been fully explored. Therefore, we investigated the assembly 
and disassembly of CPMV–dendrimer hybrids, their IP 
trafficking, and efficacy of treatment using them in a mouse 
model of ovarian cancer.
2. Results and Discussion
2.1. Formation of the CPMV-G4 Assembly
CPMV was propagated in and isolated from black-eyed pea 
plants.[20] Molecular farming of pharmaceuticals in plants is 
advantageous because plant-based production avoids contami-
nation with mammalian pathogens or contaminants such as 
endotoxins. In recent years, plant virus-based nanotechnologies 
have been recognized for their possible applications in human 
health. Their well-defined nanoscale structures in combina-
tion with genetic and chemical programmability make them an 
attractive platform technology.[21,22] CPMV is the type member 
of the comovirus genus in the family Comoviridae. Members 
of this family are also known as plant picorna-like viruses as 
they share similarities in structure, genome organization, and 
replication strategy with animal picornaviruses. CPMV infects 
legumes and was first reported in Vigna unguiculata. In sys-
temic infected plants CPMV typically causes mosaic or mot-
tling symptoms.[23] CPMV has a bipartitite positive-sense RNA 
genome encapsidated separately in isometric, icosahedral nano-
particles measuring 30 nm in diameter. The structure of CPMV 
is known to near atomic resolution. The virions are formed 
by 60 copies each of a small and large coat protein yielding a 
pseudo T = 3 symmetry.[24]
While the CPMV structure, like any proteinaceous macro-
molecule, is zwitterionic and patchy in nature, the electrostatic 
surface map and zeta potential measurement indicate that the 
net surface charge is negative (ζ = −12 mV), thus enabling 
coassembly with positively charged polymers.[19] Figure 1A 
depicts the overall assembly scheme; the electrostatically driven 
assembly of the CPMV nanoparticles with the amine-ter-
minated generation 4 PAMAM dendrimer was investigated 
through dynamic light scattering (DLS) measurements. Com-
bining both, CPMV and G4, at a concentration of 0.15 mg mL−1 
each in pure MilliQ water immediately resulted to an increase 
in hydrodynamic radius RH; from 15 nm (for CPMV), 56% 
of the assembly increased to an RH of 71 ± 5 nm, while 44% 
measured to be 841 ± 363 nm. Increasing the ionic strength 
to 10 × 10−3 m NaCl abruptly induced the formation of larger 
aggregates with diameters greater than 1.5 µm (97% of the 
assemblies). These large aggregates, which constituted at least 
96% of the assemblies, were observed at salt concentrations up 
to 150 × 10−3 m; higher concentrations gradually disassembled 
the CPMV-G4 aggregates, with concentrations greater than 
200 × 10−3 m forming aggregates with two RH distributions aver-
aging at 10–13 nm (25% of the assemblies) and 200–350 nm 
(75–78% of the assemblies) (Figure 1B). A similar trend was 
observed when a related experiment was conducted with 
increasing phosphate buffered saline (PBS) concentration. From 
0.07 to 0.36 × PBS, which corresponds to approximately NaCl 
concentrations of 10 to 50 × 10−3 m, 95–99% of the assemblies 
reached an RH between 1.3 to 2 micrometers; less than 5% of the 
assemblies had diameters less than 150 nm. The hydrodynamic 
radius of the assemblies gradually decreased starting at PBS 
concentrations higher than 0.36 ×, while other smaller aggre-
gates with RH < 10 nm start to be observed as well (Figure 1C). 
At 3.65 × PBS, 7% of the assemblies have an RH of 14 nm, 
which may correspond to CPMV; 65% resulted to 2.46 nm 
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which could be aggregated PAMAM dendrimers; only 30% of 
the assemblies maintained an RH of ≈250 nm. Complete list 
of the average hydrodynamic radius values, polydispersity index 
and percent composition of the aggregates in NaCl and PBS 
environments are presented in Tables S1 and S2 in the Sup-
porting Information. These data indicate that the presence of a 
low salt concentration promotes formation of larger aggregates; 
while CPMV and the G4 dendrimers still have some interaction 
at zero salt concentration, as indicated by the measured hydro-
dynamic radius of 70 nm for 56% of the assembly, the repulsion 
between the positively charged G4 limits greater aggregation in 
the absence of ions for some electrostatic shielding. When the 
salt level is increased too high however, salt screening effects 
limit the interactions between the dendrimers and CPMV, thus 
reducing overall aggregate size. These properties are thought 
to be useful for in vivo biomedical applications, i.e., the use of 
slow-release formulation: at low salt the assembly is triggered, 
and postinjection into the tissue, under physiologic salt concen-
trations (136–145 × 10−3 m),[25] disassembly and CPMV release 
is induced.
The stability of the CPMV-G4 assembly was investigated by 
storing the mixture in a low ionic strength environment (25 × 
10−3 m NaCl) for a week, disassembled by gradually increasing 
the salt concentration, and held in high ionic strength conditions 
(300 × 10−3 m NaCl) for another week. The assembly maintained 
its large hydrodynamic radius at low salt concentrations for 7 d. 
Exposure to higher ionic concentrations (150–300 × 10−3 m NaCl) 
led to a burst release into smaller aggregates with an RH of 500 nm; 
then slow decrease in size that may indicate slow-release of 
CPMV from the smaller aggregates (Figure 1D).
For animal studies, the concentration of CPMV was 
increased to 2.5 mg mL−1 to form larger aggregates and 
reduce the total volume of injection necessary, this concen-
tration resulted in aggregates large enough to immediately 
become visible upon mixing but still capable of being resus-
pended in solution and passed easily through a syringe. The 
CPMV:G4 ratio was maintained at 1:1 and salt concentration 
was kept low (25 × 10−3 m NaCl). Due to the high concentra-
tion of CPMV and G4, large aggregates formed immediately 
and RH could not be determined by DLS, supporting that the 
aggregates were at least larger than 2.5 µm. A cloudy appear-
ance was observed immediately and aggregates were collected 
at the bottom of the tube following a brief spin using a tab-
letop centrifuge following a 30 s spin in a tabletop centrifuge 
at 15 000 × g, indicating successful formation of CPMV–den-
drimer aggregates (Figure 1E). UV–vis spectroscopy of the 
supernatant from these aggregates was found to be below the 
linear range for detection of protein in solution indicating that 
there is minimal CPMV remaining in the supernatant and the 
overwhelming majority of CPMV interacts with PAMAM-G4 
to form the visible aggregates (Figure S1, Supporting Infor-
mation). The colloidal suspension was mixed well prior to use 
in animals.
The morphologies of the assemblies were further investi-
gated through tapping mode-atomic force microscopy (AFM). 
A 0.15 mg mL−1 solution of CPMV, in the absence of the G4 
Adv. Sci. 2018, 5, 1700991
Figure 1. A) Schematic illustration of the assembly of CPMV with PAMAM-G4 dendrimer (space model with minimized energy calculated using Spartan 
software). DLS measurements for the assembly and disassembly of CPMV and PAMAM-G4 dendrimer in B) increasing NaCl and C) PBS concentra-
tions. D) Stability study for the CPMV-G4 assembly, wherein the ionic strength was initially fixed at 25 × 10−3 m NaCl for 1 week, gradually increased, 
and was kept at 300 × 10−3 m NaCl for another 7 d. E) Aggregates of high concentration (2.5 mg mL−1) CPMV and PAMAM-G4 in 25 × 10−3 m NaCl, 
UV–vis spectroscopy of the supernatant from these aggregates was found to be below the linear range for detection of protein in solution indicating 
that there is minimal CPMV remaining in the solution (Figure S1, Supporting Information).
www.advancedsciencenews.com
1700991 (4 of 8) © 2018 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedscience.com
dendrimer, shows areas of packed CPMV 
when cast on a freshly cleaved mica sur-
face, however the presence of large empty 
spaces demonstrates that there are not 
strong interactions between the nanoparticles 
(Figure 2A). In contrast, when 0.15 mg mL−1  
CPMV is mixed with G4 at a 1:1 ratio in a 
salt-free solution, particles form large areas 
of tightly packed CPMV nanoparticles on 
the surface (Figure 2B). Increasing the ionic 
concentration to 50 × 10−3 m NaCl induced 
formation of stacks of packed CPMV nano-
particles (Figure 2C), indicating further 
increased interactions between CPMV and 
the G4 dendrimers. At higher ionic concen-
tration (150 × 10−3 m NaCl) a layer of tightly 
arranged CPMV formed, similar to the for-
mation observed in the absence of salt (Figure 
2B,D), supporting the conclusion that high 
salt concentrations reduce formation of large 
aggregations. Overall, the morphological vari-
ations of the CPMV-G4 assembly correlate 
to the DLS hydrodynamic radius measure-
ments, which exhibit the responsive assembly 
and disassembly of the electrostatic interactions as a function of 
salt concentration.
These findings are in agreement with previous work showing 
that increasing salt concentrations reduce the size of aggregate 
formation through reducing electrostatic interactions between 
dendrimers and viral nanoparticles.[26–28] While salt concentra-
tion has been known to be important in the assembly forma-
tion of virus–dendrimer hybrid materials, to our knowledge, 
the disassembly of these hybrid materials has not been investi-
gated or utilized for biomedicine.
Together, our data indicate that while the larger aggregates 
are stable for extended periods of time at low salt concentra-
tions, the larger structures disassemble at ionic concentra-
tions found in the IP space, sodium concentrations in the 
IP space are similar or slightly lower than found in serum 
(136–145 × 10−3 m).[25,29] Even at the highest salt concentration 
measured however, CPMV-G4 aggregates would still be too 
large to passively diffuse across blood vessels to enter systemic 
circulation from the intraperitoneal space (size limit < 100 nm) 
and would require disassembly or lymphatic drainage for even-
tual clearance.[30] Further, the slow time course of disassembly 
of the aggregates at physiological salt concentrations (Figure 
1C), makes this assembly a promising candidate for continued 
presence in the IP space with slow release over time.
2.2. Treatment of Ovarian Cancer in a Syngeneic Mouse Model
Treatment efficacy of the CPMV-G4 formulation was assessed 
using an aggressive, syngeneic, and orthotopic mouse model 
of ovarian cancer.[31] To monitor tumor development, we trans-
fected the cells with luciferase.[32] Treatment was started 1 week 
following injection of 2 million ID8-Defb29/Vegf-A-Luc cells into 
the IP space using female C57BL/6 mice. Establishment of dis-
ease was confirmed and then monitored using in vivo imaging 
system (IVIS) imaging. Groups were treated with the following 
treatments: a single dose of 1 mg of CPMV versus a single 
dose 1 mg CPMV equivalent of CPMV-G4 versus 100 µg of 
free CPMV administered weekly (100 µg per week is the dosing 
previously shown to be effective at treating ovarian cancer 
growth[6]); intraperitoneal PBS was administered as a control. 
An additional study compared 1 mg PAMAM-G4 alone to 1 mg 
CPMV equivalent of CPMV-G4. A dose of 1 mg was chosen for 
delayed release formulations as it provides a high enough ini-
tial dose for continuous release while still being well tolerated 
in treated animals. Disease burden was monitored twice weekly 
by tracking total luminescence indicating cancer cell growth. As 
it is difficult to directly compare tumor growth curves in studies 
not conducted at the same time these studies are plotted sepa-
rately (Figure 3A,B).
Tumor burden in mice treated with a single dose of CPMV-G4 
(1 mg) was very similar to total luminescence observed in mice 
treated weekly with soluble CPMV (100 µg), and both treatment 
groups had significantly delayed cancer cell growth (Figure 3). 
In contrast, a single 1 mg dose of soluble CPMV did not slow 
tumor growth, indicating that not the total dose but the treat-
ment schedule, (maintaining the therapeutic CPMV concen-
tration within the IP space over prolonged periods), is critical 
(Figure 3). The G4 administered alone did not have a signifi-
cant effect on tumor growth—while not statistically significant, 
there is trend that tumors grow slower in mice treated with G4, 
likely due to nonspecific cytotoxicity and immune stimulation 
associated with PAMAM dendrimers.[33,34]
Together these studies indicate that CPMV-G4 assemblies 
can function as depots for slow-release of the CPMV in situ vac-
cine, prolonging its therapeutic efficacy in a mouse model of 
ovarian cancer after a single IP administration. The retention 
of CPMV when administered as soluble versus assembled for-
mulation in the IP space was further tested by examining the 
biodistribution of fluorescently labeled CPMV and CPMV-G4.
Adv. Sci. 2018, 5, 1700991
Figure 2. Topographical tapping-mode AFM images of A) 0.15 mg mL−1 CPMV and 0.15 mg mL−1 
CPMV-G4 (1:1) in B) 0 × 10−3 m, C) 50 × 10−3 m, and D) 150 × 10−3 m NaCl, which were drop-
casted on a freshly cleaved mica surface.
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2.3. Biodistribution of CPMV-G4 Adminis-
tered Intraperitoneally
The biodistribution and clearance rate of 
CPMV compared to CPMV-G4 was evaluated 
using in vivo fluorescence imaging (Spectrum 
BLI). Mice without tumors were injected with 
1 mg of CPMV labeled with AlexaFluor 647 
either as free CPMV or formulated as the 
CPMV-G4 assembly as described above. 
CPMV nanoparticles were covalently func-
tionalized with NHS-AF647 dye molecules 
using the exposed lysine residues on the 
capsid surface. The successful chemical labe-
ling of the CPMV particles post purification 
was verified using UV–vis absorption spec-
troscopy; an average of 40 dye molecules per 
CPMV were attached (Figure 4A). A sodium 
dodecyl sulfate (SDS) gel electrophoresis 
was also conducted to confirm the cova-
lent conjugation of AF647 dye molecules to 
the CPMV coat proteins (Figure 4B). Under 
white light, bright blue bands were observed 
matching the small and large subunit pro-
teins of CPMV-AF647, which was not evident 
Adv. Sci. 2018, 5, 1700991
Figure 3. Growth of ovarian cancer cells in the intraperitoneal space. Treatment was injected 
intraperitoneally 7 d following injection of 2 million luciferase-positive ID8-Def29/Vegf-A cells. 
Injection of each treatment group is indicated with a color-coordinated arrow. PBS was also 
injected weekly. Total bioluminescence was measured in intraperitoneal space until ascites 
development was apparent in the PBS control group (n = 5–6). PBS/weekly in black, G4/1 mg 
once (normalized to the amount of G4 in CPMV-G4) in blue, CPMV-G4/1 mg once in purple, 
CPMV/1 mg weekly in orange, CPMV/100 µg weekly in red, CPMV/1 mg once in green. Graphs 
represent two successive experiments. (*p < 0.05 as calculated by Excel two-tailed t-test when 
treatment group is compared to PBS, no statistical difference was found was between G4 only 
and PBS or a PBS and a single injection of CPMV 1 mg).
Figure 4. Characterization of dye-labeled CPMV and CPMV-G4 assemblies. A) Representative UV–vis absorption spectra of AF647, CPMV, and CPMV-
AF647 particles. B) SDS-PAGE analysis of wild type CPMV and CPMV-AF647 in white light and after Coomassie Blue staining. C) Free CPMV-AF647 and 
aggregates of CPMV-AF647-G4 immediately following mixing and after a brief spin in a table-top centrifuge (aggregates are too large to be measured 
with DLS).
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for CPMV; staining with Coomassie Blue, shows that CPMV 
coat proteins are colocalized with the dye. Successful assembly 
of fluorescent AF647-CPMV-G4 formulation was confirmed by 
immediate visual changes in the mixture as well as accumula-
tion in the bottom of a centrifuge tube following a 30 s spin on a 
tabletop centrifuge (at 15 000 g) (Figure 4C).
Biodistribution was then determined using a longitudinal 
imaging approach; at defined time points over a 14 d course, 
total fluorescence in the IP space was determined using Spec-
trum BLI and region of interest (ROI) analysis (Figure 5). Free 
CPMV was cleared from the IP space more quickly than CPMV-
G4; ≈50% of the maximal measured fluorescence intensity was 
present for free CPMV at 7 d, in contrast over 50% of the max-
imal measured fluorescence intensity in CPMV-G4 treated ani-
mals persisted at day 14. Overall CPMV-G4 has roughly a 3 fold 
longer half-life in the peritoneum than free CPMV. Both groups 
showed an initial increase in measured fluorescent intensity, 
likely due to a reduction in the fluorescence quenching of the 
fluorophores;[35] perhaps as the CPMV spread throughout the 
IP space, the overall concentration of fluorophores was reduced 
and measured fluorescence increased. To prevent this early 
quenching from causing artificially high percent retention to 
be calculated, relative fluorescence intensity was calculated 
from the maximum fluorescence measured and not the initial 
intensity measurement. While this quenching effect limits the 
utility of in vivo fluorescent imaging to determine the absolute 
concentration of CPMV still present in the IP space, it still 
provides useful information as to the relative speed at which 
free CPMV and CPMV-G4 assembly is cleared and supports 
enhanced retention of CPMV in the CPMV-G4 assembly com-
pared to free CPMV.
These biodistribution studies are in good agreement with the 
efficacy studies that show a single administration of CPMV-G4 
was as effective as weekly injections of free CPMV (Figure 3). This 
confluence of data supports the conclusion that CPMV, when 
formulated as CPMV-G4 assemblies, forms a depot and is detach-
able over prolonged periods of time, continually stimulating anti-
tumor immunity. For this depot strategy of in situ vaccination to 
be effective, the depots must be retained within the peritoneal 
site of ovarian cancer. We hypothesize that the larger CPMV-G4 
aggregates are not easily cleared through leaking into blood ves-
sels or lymphatic drainage in the IP space without disassembly.
Compared to other systems, the observed retention time 
for CPMV-G4 is longer; for example polymer-based hydro-
gels injected intraperitoneally were found to persist at 8 d 
following injection.[36] Further, while hyaluronic acid based 
hydrogels have been shown to persist in the IP space for a com-
parable or longer time, their use as a drug carrier has led to 
both decreased[37,38] and increased tumor growth,[39] indicating 
that further investigation of this system, especially its degra-
dation byproducts, is needed before it can be considered for 
use in slow-release formulations. Finally, our system has sev-
eral advantages over other types of slow-release formulations 
including implantable devices that typically require an invasive 
surgery;[40] the virus–dendrimer colloidal solution is nonviscous 
and can be administered with a syringe without surgical inter-
vention. As with any nanotechnology, the advantages and disad-
vantages must be carefully considered; unlike plant-virus based 
materials, PAMAM dendrimers have been shown to be toxic at 
high concentrations and further study of the in vivo properties 
of dendrimers and associated hybrid materials is still needed 
in order to better understand associated toxicity and interaction 
with the immune system.[33,34,41] Future studies may explore the 
assembly with other polymeric systems.
3. Conclusions
Virus–dendrimer hybrid materials are a novel class of materials 
with a number of potential applications targeting materials and 
human health. Here we present the application of the CPMV-G4 
Adv. Sci. 2018, 5, 1700991
Figure 5. Retention of CPMV and CPMV-G4 in the intraperitoneal space. 
A) Fluorescence imaging of C57/BL6 mice immediately following injec-
tion, on days 3, 7, and 14. B) Normalized fluorescent intensity as deter-
mined by ROI analysis; the highest measured fluorescence intensity in 
the intraperitoneal space over the course of the study was established as 
1 and relative intensity for all subsequent time-points was calculated as a 
portion of this intensity (n = 3).
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hybrid assembly as an immunotherapy; specifically the 
assembly functions as a depot with slow release of the immu-
nostimulatory nanoparticle CPMV in the IP cavity, therefore 
prolonging its therapeutic antitumor effect in a mouse model 
of IP disseminated ovarian cancer. A single administration of 
the CPMV-G4 hybrid resulted in matched efficacy compared to 
weekly treatment using the soluble CPMV formulation. This is 
an important finding and may enable the in situ vaccine appli-
cation of CPMV assemblies for difficult to inject tumors, such 
as ovarian cancer or gliomas; in these disease settings reducing 
the number of necessary administrations while maintaining 
a potent immunotherapy effect is an important goal to enable 
successful translation of in situ applied (immune)therapeutics.
4. Experimental Section
Preparation of CPMV Nanoparticles and Generation 4 PAMAM 
Dendrimer: CPMV was propagated in black-eyed pea plants 
(V. unguiculata) and isolated using previously reported protocols.[42]
For biodistribution studies, the CPMV particles were conjugated 
with an Alexa Fluor 647 dye (NHS-AF647) using a previously described 
reaction.[35] In brief, dye labeling was carried out overnight at a 
concentration of 2 mg mL−1 CPMV in 0.1 m potassium phosphate buffer 
(pH 7.0) and 10% DMSO with an excess of 2000 dyes per CPMV. 
The dye-functionalized CPMV particles (CPMV-AF647) were purified 
by ultracentrifugation and characterized using UV–vis absorption 
spectroscopy using a Nanodrop instrument. Dyes per particle were 
determined using the extinction coefficients and absorption maximums 
8.1 mg−1cm−1 at 260 nm for CPMV[35] and 270 000 m−1 cm−1 at 650 nm 
for AF647 (per company website). Attachment was confirmed with 
electrophoresis using 4–12% NuPage bis-tris gels (Invitrogen).
Generation 4 PAMAM dendrimers with an ethylenediamine core 
(10 wt% in methanol) used in the study was purchased from Sigma 
Aldrich. PAMAM-G4 was isolated by removing methanol through 
rotary evaporation and resuspended in MilliQ water at a 10 mg mL−1 
concentration.
Dynamic Light Scattering: To study the assembly and disassembly of 
CPMV-G4 DLS measurements were performed: CPMV (≈50 mg mL−1 
in 0.1 m PBS, pH 7.0) and PAMAM-G4 dendrimers (10 mg mL−1 in 
MilliQ water) were mixed at 0.15 mg mL−1 of virus and 0.15 mg mL−1 
dendrimer concentration. The ionic strength was modified by adding 
small amounts of either 2 m NaCl or 10 × PBS stock solutions. The 
hydrodynamic radius of the virus–polymer assemblies was measured 
using a DynaPro Nanostar DLS instrument (Wyatt Technology, Goleta, 
CA) at a wavelength of 658 nm, 90° scattering angle, 25 °C.
Atomic Force Microscopy: The morphology of the CPMV-G4 
assemblies was imaged using a 5500 atomic force microscope (Keysight 
Technologies, Inc., formerly Agilent Technologies) in tapping mode. 
High-resolution noncontact gold-coated NSG30 silicon cantilevers 
(NT-MDT Spectrum Instruments, Tempe, AZ) with a resonant frequency 
of 240–440 kHz were used and mounted onto the piezoelectric scanner 
for AFM imaging. The resulting AFM images were processed using 
Gwyddion Ver. 2.47.
Ovarian Cancer In Vivo Efficacy and Biodistribution: Animal studies 
were carried out using IACUC-approved protocols. Female C57BL/6 
mice (Jackson Labs) were injected intraperitoneally with 2 million cells 
of the highly aggressive, luciferase-positive, murine ovarian cancer cell 
line ID8-Defb29/Vegf-A in sterile PBS. ID8-Defb29/Vegf-A cells were 
transfected with luciferase as previously described.[32] Cancer cell growth 
was monitored using the Perkin Elmer IVIS Spectrum; mice were injected 
intraperitoneally with luciferin (15 mg mL−1, 150 µL intraperitoneally) 
and imaged 5 min postinjection with a 3 min exposure time. Total 
luminescence was determined using Living Image software and total 
counts per mouse were graphed. Treatment was initiated 7 d following 
cell injection and administered either weekly (PBS and CPMV 100 µg 
per mouse) or once (1 mg CPMV and 1 mg CPMV in the described 
CPMV-G4 assembly). CPMV-G4 was vortexed immediately prior to 
injection. Prior to treatment group assignment, total luminescence 
was determined on day seven and used to match total cancer burden 
between treatment groups (n = 5–6).
For biodistribution studies, mice were injected with 2 million ID8-
Defb29/Vegf-Luc cells intraperitoneally and cancer cells were allowed 
to grow for 1 week. Following establishment of intraperitoneal disease 
as determined by IVIS imaging, mice were injected with PBS, 1 mg of 
AF647-CPMV, or 1 mg of AF647-CPMV-G4. Mice were imaged prior to 
injection, immediately after injection, and at times 1 h, 3h, 6 h, 12 h, 
24 h, 48 h, 72 h, 7 d, 11 , and 14 d. Images were obtained in Spectral 
unmixing mode and each time-point was unmixed to isolate AF647 
signal using the same library; an unmixing library was established 
separately for each cage immediately following injection. ROI analysis 
was performed on unmixed images from each time-point and radiant 
efficiency ((p s−1 cm−2)/(µW cm−2)). Graphed relative fluorescence 
intensities are a summary of two successive biodistribution studies of 
n = 1 followed by n = 2.
Supporting Information
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from the author.
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